FINWIRES · TerminalLIVE
FINWIRES

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

By

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.

Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.

The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.

Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."

RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.

Price: $9.84, Change: $+0.13, Percent Change: +1.29%

Related Articles

Wire

Workiva Q1 Adjusted Earnings, Revenue Rise; Shares Drop After Hours

Workiva (WK) reported Q1 adjusted earnings late Tuesday of $0.77 per diluted share, up from $0.14 a year earlier.Analysts polled by FactSet expected $0.65.Revenue for the three months ended March 31 rose to $247.3 million from $206.3 million a year earlier.Analysts surveyed by FactSet expected $245.2 million.Workiva expects Q2 adjusted EPS of $0.62 to $0.65 on revenue of $250 million to $252 million. Analysts expect EPS of $0.52 on revenue of $252.1 million.The company expects full-year adjusted EPS of $2.85 to $2.95 on revenue of $1.037 billion to $1.041 billion. Analysts expect EPS of $2.71 on revenue of $1.038 billion.Workiva shares fell 4.4% in after-hours trading.

$WK
Wire

SSR Mining Q1 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

SSR Mining (SSRM) reported Q1 adjusted earnings late Tuesday of $1.15 per diluted share, up from $0.41 a year earlier.Analysts polled by FactSet expected $0.84.Revenue in the three months ended March 31 rose to $581.8 million from $316.6 million a year earlier.Four analysts surveyed by FactSet expected $536.4 million.SSR Mining shares rose 8% in after-hours trading.

$SSRM
Wire

Everus Construction Q1 Earnings, Revenue Rise; Shares Gain After Hours

Everus Construction Group (ECG) reported Q1 earnings late Tuesday of $1.14 per diluted share, up from $0.72 a year earlier.Analysts surveyed by FactSet expected $0.81.Revenue for the three months ended March 31 rose to $1.04 billion from $826.6 million a year earlier.Analysts polled by FactSet expected $933.8 million.The company raised full-year revenue guidance to $4.3 billion to $4.4 billion from the prior forecast of $4.1 billion to $4.2 billion.Analysts expect $4.23 billion.Everus shares rose 4.2% in after-hours trading.

$ECG